vents. Both drugs are substrates and inhibitors of the drug transporter P-glycoprotein (P-gp). In addition, clarithromycin is a potent inhibitor of the hepatic enzyme CYP3A4. Velpatasvir is a CYP3A4 substrate.
Clobazam: Use caution when administering velpatasvir with clobazam. Taking these drugs together may decrease velpatasvir plasma concentrations, potentially resulting in loss of antiviral efficacy. Velpatasvir is a CYP3A4 substrate; clobazam is a weak inducer of CYP3A4. Additionally, velpatasvir is an inhibitor of the drug transporter P-glycoprotein (P-gp). Coadministration with substrates of this transporter, such as clobazam, may increase their exposure.
Cobicistat: Caution is warranted when cobicistat is administered with sofosbuvir as there is a potential for elevated concentrations of sofosbuvir. Clinical monitoring for adverse effects is recommended during coadministration. Cobicistat is an inhibitor of the transporters P-glycoprotein and breast cancer resistance protein (BCRP). Sofosbuvir is a substrate of P-gp and BCRP. According to the manufacturer, no dosage adjustments are required when sofosbuvir is administered concurrently with P-gp or BCRP inhibitors. Use caution when administering velpatasvir with cobicistat. Taking these drugs together may increase the plasma concentrations of velpatasvir, potentially resulting in adverse events. Velpatasvir is a substrate of the drug transporters P-glycoprotein (P-gp) and Breast Cancer Resistance Protein (BCRP); cobicistat is an inhibitor of P-gp and BCRP. Cobicistat is also an inhibitor of the hepatic enzyme CYP3A4. Velpatasvir is a CYP3A4 substrate.
Cobicistat; Elvitegravir; Emtricitabine; Tenofovir Alafenamide: Caution is warranted when cobicistat is administered with sofosbuvir as there is a potential for elevated concentrations of sofosbuvir. Clinical monitoring for adverse effects is recommended during coadministration. Cobicistat is an inhibitor of the transporters P-glycoprotein and breast cancer resistance protein (BCRP). Sofosbuvir is a substrate of P-gp and BCRP. According to the manufacturer, no dosage adjustments are required when sofosbuvir is administered concurrently with P-gp or BCRP inhibitors. Monitor patients for tenofovir-associated adverse reactions, such as renal toxicity, in patients receiving regimens containing tenofovir alafenamide and velpatasvir due to potential increases in tenofovir serum concentrations. Tenofovir alafenamide is a substrate of the breast cancer resistance protein (BCRP),P-glycoprotein (P-gP), OATP1B1, and OATB1B3 transporters, while velpatasvir inhibits these transporters. Use caution when administering velpatasvir with cobicistat. Taking these drugs together may increase the plasma concentrations of velpatasvir, potentially resulting in adverse events. Velpatasvir is a substrate of the drug transporters P-glycoprotein (P-gp) and Breast Cancer Resistance Protein (BCRP); cobicistat is an inhibitor of P-gp and BCRP. Cobicistat is also an inhibitor of the hepatic enzyme CYP3A4. Velpatasvir is a CYP3A4 substrate.
Cobicistat; Elvitegravir; Emtricitabine; Tenofovir Disoproxil Fumarate: Caution is warranted when cobicistat is administered with sofosbuvir as there is a potential for elevated concentrations of sofosbuvir. Clinical monitoring for adverse effects is recommended during coadministration. Cobicistat is an inhibitor of the transporters P-glycoprotein and breast cancer resistan |
